U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Pleural Malignant Mesothelioma

MedGen UID:
1686266
•Concept ID:
C5206948
•
Neoplastic Process

Definition

Pleural malignant mesothelioma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Pleural Malignant Mesothelioma

Professional guidelines

PubMed

True Benefits of Immune Checkpoint Inhibitors in the Treatment of Malignant Pleural Mesothelioma in Japan.
Kuribayashi K, Hirano J
Anticancer Res 2024 Oct;44(10):4135-4145. doi: 10.21873/anticanres.17244. PMID: 39348972
Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
Tamanna MT, Egbune C
Cancer Treat Res 2023;185:79-89. doi: 10.1007/978-3-031-27156-4_5. PMID: 37306905
Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.
Favoni RE, Daga A, Malatesta P, Florio T
Br J Pharmacol 2012 May;166(2):532-53. doi: 10.1111/j.1476-5381.2012.01873.x. PMID: 22289125Free PMC Article

Recent clinical studies

Etiology

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
Zauderer MG, Szlosarek PW, Le Moulec S, Popat S, Taylor P, Planchard D, Scherpereel A, Koczywas M, Forster M, Cameron RB, Peikert T, Argon EK, Michaud NR, Szanto A, Yang J, Chen Y, Kansra V, Agarwal S, Fennell DA
Lancet Oncol 2022 Jun;23(6):758-767. Epub 2022 May 16 doi: 10.1016/S1470-2045(22)00277-7. PMID: 35588752
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
Expression of Numb and Gli1 in malignant pleural mesothelioma and their clinical significance.
Zhang C, Kang Y, Ma R, Chen F, Chen F, Dong X
J Cancer Res Ther 2018 Jul-Sep;14(5):970-976. doi: 10.4103/0973-1482.180614. PMID: 30197333
Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study.
Von Hoff DD, Metch B, Lucas JG, Balcerzak SP, Grunberg SM, Rivkin SE
J Interferon Res 1990 Oct;10(5):531-4. doi: 10.1089/jir.1990.10.531. PMID: 2273299
Peritoneovenous shunt for intractable malignant ascites. A single case report of metastatic peritoneal mesothelioma implanted via LeVeen shunt.
Nervino HE, Gebhardt FC
Cancer 1984 Nov 15;54(10):2231-3. doi: 10.1002/1097-0142(19841115)54:10<2231::aid-cncr2820541027>3.0.co;2-i. PMID: 6207908

Diagnosis

Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
Tamanna MT, Egbune C
Cancer Treat Res 2023;185:79-89. doi: 10.1007/978-3-031-27156-4_5. PMID: 37306905
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL
Mol Ther 2019 Nov 6;27(11):1919-1929. Epub 2019 Jul 30 doi: 10.1016/j.ymthe.2019.07.015. PMID: 31420241Free PMC Article
Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.
Truini A, Coco S, Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, Rijavec E, Barletta G, Biello F, Maggioni C, Grossi F
Microrna 2016;5(1):12-18. doi: 10.2174/2211536605666160128151018. PMID: 26817512
Malignant mesothelioma of the tunica vaginalis testis: a malignancy associated with recurrent epididymitis?
Yen CH, Lee CT, Su CJ, Lo HC
World J Surg Oncol 2012 Nov 9;10:238. doi: 10.1186/1477-7819-10-238. PMID: 23140511Free PMC Article
Antiangiogenic therapies for malignant pleural mesothelioma.
Yano S, Li Q, Wang W, Yamada T, Takeuchi S, Nakataki E, Ogino H, Goto H, Nishioka Y, Sone S
Front Biosci (Landmark Ed) 2011 Jan 1;16(2):740-8. doi: 10.2741/3716. PMID: 21196199

Therapy

New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
Tsao AS, Pass HI, Rimner A, Mansfield AS
J Clin Oncol 2022 Feb 20;40(6):681-692. Epub 2022 Jan 5 doi: 10.1200/JCO.21.01567. PMID: 34985934Free PMC Article
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL
Mol Ther 2019 Nov 6;27(11):1919-1929. Epub 2019 Jul 30 doi: 10.1016/j.ymthe.2019.07.015. PMID: 31420241Free PMC Article
Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".
Di Noia V, Vita E, Ferrara M, Strippoli A, Basso M, Schinzari G, Cassano A, Bria E, Barone C, D'Argento E
Curr Treat Options Oncol 2019 Feb 21;20(3):23. doi: 10.1007/s11864-019-0616-7. PMID: 30790063
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
Calabrò L, Ceresoli GL, di Pietro A, Cutaia O, Morra A, Ibrahim R, Maio M
Cancer Immunol Immunother 2015 Jan;64(1):105-12. Epub 2014 Sep 19 doi: 10.1007/s00262-014-1609-9. PMID: 25233793Free PMC Article
Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study.
Von Hoff DD, Metch B, Lucas JG, Balcerzak SP, Grunberg SM, Rivkin SE
J Interferon Res 1990 Oct;10(5):531-4. doi: 10.1089/jir.1990.10.531. PMID: 2273299

Prognosis

New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
Tsao AS, Pass HI, Rimner A, Mansfield AS
J Clin Oncol 2022 Feb 20;40(6):681-692. Epub 2022 Jan 5 doi: 10.1200/JCO.21.01567. PMID: 34985934Free PMC Article
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.
Truini A, Coco S, Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, Rijavec E, Barletta G, Biello F, Maggioni C, Grossi F
Microrna 2016;5(1):12-18. doi: 10.2174/2211536605666160128151018. PMID: 26817512
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
Calabrò L, Ceresoli GL, di Pietro A, Cutaia O, Morra A, Ibrahim R, Maio M
Cancer Immunol Immunother 2015 Jan;64(1):105-12. Epub 2014 Sep 19 doi: 10.1007/s00262-014-1609-9. PMID: 25233793Free PMC Article
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Pishchik V, Figg WD, Murgo AJ, Steinberg SM
Clin Cancer Res 2006 Oct 1;12(19):5777-85. doi: 10.1158/1078-0432.CCR-06-0669. PMID: 17020984

Clinical prediction guides

New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
Tsao AS, Pass HI, Rimner A, Mansfield AS
J Clin Oncol 2022 Feb 20;40(6):681-692. Epub 2022 Jan 5 doi: 10.1200/JCO.21.01567. PMID: 34985934Free PMC Article
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
Molecular pathogenesis of malignant mesothelioma.
Sekido Y
Carcinogenesis 2013 Jul;34(7):1413-9. Epub 2013 May 14 doi: 10.1093/carcin/bgt166. PMID: 23677068
Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study.
Scherpereel A, Berghmans T, Lafitte JJ, Colinet B, Richez M, Bonduelle Y, Meert AP, Dhalluin X, Leclercq N, Paesmans M, Willems L, Sculier JP; European Lung Cancer Working Party (ELCWP)
Eur Respir J 2011 Jan;37(1):129-35. Epub 2010 Jun 7 doi: 10.1183/09031936.00037310. PMID: 20530048
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Pishchik V, Figg WD, Murgo AJ, Steinberg SM
Clin Cancer Res 2006 Oct 1;12(19):5777-85. doi: 10.1158/1078-0432.CCR-06-0669. PMID: 17020984

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...